999 related articles for article (PubMed ID: 26826304)
1. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
2. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
3. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
4. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
5. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery.
Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260
[TBL] [Abstract][Full Text] [Related]
8. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
[TBL] [Abstract][Full Text] [Related]
9. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid nanogels prepared via ortho ester linkages show pH-triggered behavior, enhanced penetration and antitumor efficacy in 3-D tumor spheroids.
Yang G; Fu S; Yao W; Wang X; Zha Q; Tang R
J Colloid Interface Sci; 2017 Oct; 504():25-38. PubMed ID: 28527297
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration.
Wan J; Geng S; Zhao H; Peng X; Zhou Q; Li H; He M; Zhao Y; Yang X; Xu H
J Control Release; 2016 Aug; 235():328-336. PubMed ID: 27282415
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
Eliaz RE; Szoka FC
Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
[TBL] [Abstract][Full Text] [Related]
14. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
16. Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.
Yu C; Zhou M; Zhang X; Wei W; Chen X; Zhang X
Nanoscale; 2015 Mar; 7(13):5683-90. PubMed ID: 25740312
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
[TBL] [Abstract][Full Text] [Related]
18. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
[TBL] [Abstract][Full Text] [Related]
19. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
20. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]